Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial

被引：27
|
作者：
Spaner, David E. [1 ,2 ,3 ,4 ,5 ]
Wang, Guizhei [1 ]
McCaw, Lindsay [1 ]
Li, Yanmei [1 ]
Disperati, Patricia [6 ]
Cussen, Mary-Ann [3 ]
Shi, Yonghong [1 ]
机构：
[1] Sunnybrook Res Inst, Biol Platform, Toronto, ON, Canada
[2] Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A1, Canada
[3] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[4] Univ Toronto, Dept Med, Toronto, ON M5S 1A1, Canada
[5] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A1, Canada
[6] Toronto East Gen Hosp, Toronto, ON, Canada
来源：
HAEMATOLOGICA | 2016年 / 101卷 / 05期
关键词：
chronic lymphocytic leukemia; Janus Kinases; STAT3; Ruxolitinib; Ibrutinib; Kinase inhibitors; phosphoproteome; FOLLOW-UP; RESISTANCE; THERAPY; CELLS; CLL;
D O I：
10.3324/haematol.2015.135418
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [11] Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
    Rothstein, Brooke
    Joshipura, Deep
    Saraiya, Ami
    Abdat, Rana
    Ashkar, Huda
    Turkowski, Yana
    Sheth, Vaneeta
    Huang, Victor
    Au, Shiu Chung
    Kachuk, Courtney
    Dumont, Nicole
    Gottlieb, Alice B.
    Rosmarin, David
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : 1054 - +
  • [12] Treatment of vitiligo with topical janus kinase inhibitor ruxolitinib
    Rothstein, B.
    Joshipura, D.
    Saraiya, A.
    Abdat, R.
    Ashkar, H.
    Turkowski, Y.
    Sheth, V.
    Huang, V.
    Au, S. Chung
    Kachuk, C.
    Dumont, N.
    Gottlieb, A. B.
    Rosmarin, D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S132 - S132
  • [13] Efficacy and Safety of Ruxolitinib for Treatment of Symptomatic Chronic Myelomonocytic Leukemia (CMML): Results of a Multicenter Phase II Clinical Trial
    Padron, Eric
    Tinsley-Vance, Sara M.
    DeZern, Amy E.
    Carraway, Hetty E.
    Luskin, Marlise R.
    Roboz, Gail J.
    Chan, Onyee
    Horton, Meagan
    Gerds, Aaron T.
    Sallman, David A.
    Kuykendall, Andrew
    Steensma, David
    Balasis, Maria E.
    Lancet, Jeffrey E.
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    BLOOD, 2022, 140 : 1101 - 1103
  • [14] Dasatinib Has Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL/SLL), a Phase II Trial
    Amrein, Philip C.
    Attar, Eyal
    Takvorian, Tak
    Hochberg, Ephraim
    Ballen, Karen K.
    Leahy, Kathleen M.
    Neuberg, Donna
    Brown, Jennifer R.
    BLOOD, 2008, 112 (11) : 1084 - 1084
  • [15] Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naive patients with myelofibrosis: Results of a phase II trial
    Zhang, Yi
    Zhou, Hu
    Jiang, Zhongxing
    Wu, Dengshu
    Zhuang, Junling
    Li, Wei
    Jiang, Qian
    Wang, Xiuli
    Huang, Jinwen
    Zhu, Huanling
    Yang, Linhua
    Du, Xin
    Li, Fei
    Xia, Ruixiang
    Zhang, Feng
    Hu, Jianda
    Li, Yan
    Hu, Yu
    Liu, Jing
    Jin, Chenghao
    Sun, Kai
    Zhou, Zeping
    Wu, Liqing
    Yu, Wenjuan
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (12) : 1510 - 1519
  • [16] Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia
    Lin, Thomas S.
    Naumovski, Louie
    Lecane, Philip S.
    Lucas, Margaret S.
    Moran, Mollie E.
    Cheney, Carolyn
    Lucas, David M.
    Phan, See-Chun
    Miller, Richard A.
    Byrd, John C.
    LEUKEMIA & LYMPHOMA, 2009, 50 (12) : 1977 - 1982
  • [17] Phase II trial of theophylline for early stage chronic lymphocytic leukemia (CLL).
    Makower, D
    Lee, S
    Wiernik, PH
    Paietta, E
    Bennett, JM
    Wade, J
    Ghosh, C
    Kaminer, L
    Tallman, MS
    BLOOD, 2001, 98 (11) : 290B - 290B
  • [18] Is bendamustine an ideal partner for rituximab in the management of relapsed chronic lymphocytic leukemia? Results of a multicenter Phase II trial
    Montillo, Marco
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (01) : 43 - 46
  • [19] Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial
    Ferrajoli, Alessandra
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Badoux, Xavier
    Estrov, Zeev
    Schlette, Ellen
    Smith, Susan C.
    Ayala, Ana B.
    Falchi, Lorenzo
    Calin, Steliana
    Kantarjian, Hagop M.
    Keating, Michael J.
    BLOOD, 2011, 118 (21) : 780 - 780
  • [20] Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients With Chronic Myelomonocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 18 - 19
12345